Related Experiment Video
Updated: Dec 27, 2025

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Re-imagining cystic fibrosis care: next generation thinking
Catherine Rang1, Dominic Keating1,2, John Wilson1,2
1Cystic Fibrosis Service, Dept of Respiratory Medicine, Alfred Health, Melbourne, Australia.
New modulator therapies targeting the cystic fibrosis transmembrane conductance regulator (CFTR) protein defect have significantly improved patient outcomes. While not suitable for everyone, these targeted treatments represent a major advance in cystic fibrosis care.
Area of Science:
- Medical Genetics
- Pulmonology
- Pharmacology
Background:
- Cystic Fibrosis (CF) is a common, inherited multi-system disorder.
- Advances in understanding CF pathophysiology and care have increased life expectancy.
- Recent breakthroughs focus on therapies targeting the defective CFTR protein.
Purpose of the Study:
- To review the impact of novel therapies on cystic fibrosis care.
- To discuss the benefits and limitations of CFTR modulator therapies.
- To explore the future of personalized medicine in CF management.
Main Methods:
- Review of recent clinical advancements in CF treatment.
- Analysis of small molecule agents targeting CFTR protein dysfunction.
- Discussion of clinical trial outcomes and real-world data.
Main Results:
- Small molecule CFTR modulators improve lung function and reduce exacerbations.
- These therapies enhance weight gain and quality of life for many CF patients.
- Earlier intervention with modulators is becoming a cornerstone of CF care.
Conclusions:
- CFTR modulator therapies represent a significant therapeutic advance.
- Challenges remain regarding accessibility and suitability for all CF patients.
- Personalized, targeted therapies are the future direction for CF management.
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
03:53Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Microorganisms in Medicine and Therapeutics